Abstract
Four commercially available transvenous pacing leads were evaluated in a series of 240 implants on a rotational order basis. Total (intra- and post-operative) failure rates for this series were: Cordis 1 mm, 1/60 (1.7%); Biotronik IE-65-I, 5/60 (8.3%); Medtronic 6961, 4/60 (6.7%); and CPI 4116, 6/60 (10.0%). Post-operative failure rates were: 1 mm, 1/60 (1.7%); IE-65-I, 4/59 (6.8%); 6961, 0/56 (0.0%), and 4116, 3/57 (5.3%). In a previous study conducted at this center with identical protocol, total failure rates were: Medtronic 6907, 7/76 (9.2%); Cordis CL, 7/76 (9.2%); Biotronik IE-65-I, 2/76 (2.6%); and the Vitatron MIP-2000, 9/45 (20.0%). Post-operative failure rates were: 6907, 4/73 (5.5%); CL, 6/75 (8.0%); IE-65-I, 2/76 (2.6%); and MIP-2000, 5/41 (12.2%). If the two IE-65-I series are combined, the total failure rate is 7/136 (5.1%), and the post-operative failure rate is 6/135 (4.4%). Significant differences exist between the highest and lowest failure rates in total and post-operative cases for each series. The final decision concerning use of a particular lead must, of course, be based on clinical criteria.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
